Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival
Open Access
- 29 October 2007
- journal article
- amyloidosis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (11) , 3858-3868
- https://doi.org/10.1002/art.22959
Abstract
Objective: To characterize symptoms and signs of AL amyloidosis that may bring patients to the attention of rheumatologists, evaluate Ig VL gene usage in this subgroup of patients, and assess the impact of soft tissue and bone involvement and VL gene usage on survival.Methods: Clinical features of soft tissue and bone involvement were assessed in 191 patients with AL amyloidosis. VL gene sequencing was carried out to determine light‐chain family, rate of somatic mutation, and evidence of antigen selection. The association of soft tissue and bone involvement with VL gene usage was assessed by logistic regression analysis, and survival time was analyzed using log rank tests and Cox regression models.Results: Soft tissue and bone involvement occurred in 42.9% of the patients, and 9.4% had dominant soft tissue and bone involvement. The most common manifestations were submandibular gland enlargement, macroglossia, and carpal tunnel syndrome. Dominant soft tissue and bone involvement was significantly associated with VLκI gene usage. Mutation rate and evidence of antigen selection in the VL genes were not found to be confounding factors, providing evidence against a contribution of autoimmunity in this type of AL amyloidosis. Survival time was initially longer in patients with dominant soft tissue and bone involvement than in patients with other dominant organ involvement; however, this difference diminished over time.Conclusion: Amyloid infiltration into soft tissue, joints, periarticular structures, and bones can bring patients with AL amyloidosis to the attention of rheumatologists. Recognition of the presenting symptoms is essential for accurate diagnosis and appropriate treatment, since the long‐term outlook for untreated patients with dominant soft tissue and bone involvement is not better than that for patients with other dominant features of AL amyloidosis.Keywords
This publication has 43 references indexed in Scilit:
- Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantationBone Marrow Transplantation, 2006
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005
- From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literatureClinical Rheumatology, 2005
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood, 2004
- The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burdenBlood, 2001
- Amyloid myopathy: An underdiagnosed entityAnnals of Neurology, 1998
- Primary Amyloidosis Co-Presenting with Cervical and Massive Intra-Abdominal LymphadenopathyLeukemia & Lymphoma, 1995
- Multiple Myeloma and AL Amyloidosis Mimicking SjÖgrenʼs SyndromeSouthern Medical Journal, 1993
- Multiple myeloma and amyloidosis of the tongueJournal of Oral Pathology & Medicine, 1988
- Destructive bone lesions in primary amyloidosisPublished by Oxford University Press (OUP) ,1986